MetaCap

Entrada Therapeutics (TRDA) vs Vogenx (VOGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vogenx is the larger company by market cap ($176.3 million vs $170.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TRDA-43.29%VOGX-8.69%
+173%+60%-54%
Aug 12, 20261 yearNov 20, 2026
TRDA-41.69%VOGX-19.69%
+138%+44%-50%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TRDA versus VOGX key metrics
MetricTRDAVOGX
Share price$4.35$11.87
Market cap$170.30M$176.33M
1-day change-6.25%-7.30%
YTD return-57.68%—
1-year return-56.97%—
5-year return-84.95%—
EPS (TTM)$-3.84$-0.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$25.42M—
Revenue growth (YoY)-87.94%—
Net income (latest FY)$-143.75M—
Operating margin-621.13%—
Net margin-565.48%—
52-week high$16.45$38.41
52-week low$4.11$11.51
Distance from 52-week high-73.56%-69.10%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+308.05%+363.35%
Average volume401.15K128.78K
Shares outstanding39.15M14.86M
Employees1524
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Entrada Therapeutics

TRDA stock →

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees

About Vogenx

VOGX stock →

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

TRDA vs VOGX FAQ

Which is bigger, Entrada Therapeutics or Vogenx?

Vogenx (VOGX) is larger, with a market capitalization of $176.33M compared with $170.30M for Entrada Therapeutics (TRDA).

Are Entrada Therapeutics and Vogenx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons